07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glucokinase (GCK; GK); glucokinase regulator (GCKR; GKRP)

Endocrine/metabolic disease INDICATION: Diabetes In vitro and rat studies suggest a thiazole sulfone-based disruptor of the GCK- GCKR complex could help treat Type II diabetes. Chemical synthesis and in vitro testing of aryl sulfone analogs...
08:00 , Nov 21, 2013 |  BC Innovations  |  Cover Story

Glucokinase alternative

Over the last decade, numerous compounds that activate glucokinase have advanced into the clinic to treat diabetes, but the approach has faced safety challenges because of, amongst other issues, high rates of adverse hypoglycemic events....
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Glucokinase (GCK; GK); glucokinase regulator (GCKR; GKRP) In vitro and mouse studies identified compounds that could help treat type...
07:00 , Mar 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver disease Neurocan (NCAN); glucokinaseregulator (GCKR; GKRP); lysophospholipase-like 1 (LYPLAL1); patatin-like phospholipase domain containing 3 (PNPLA3) Genomewide association studies identified...
01:27 , Apr 28, 2007 |  BC Extra  |  Clinical News

Researchers identify genetic links to diabetes

Scientists from Harvard, MIT, Lund University and Novartis (NVS; SWX:NOVN) published in Science the use of a genome-wide association study to identify three regions of the genome that influence the risk of Type II diabetes...